<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217086</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P13 3.1</org_study_id>
    <nct_id>NCT01217086</nct_id>
  </id_info>
  <brief_title>Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)</brief_title>
  <official_title>Randomized, Double-blind, Parallel-group, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the trial to see how our product is similar to remicade by comparing the results of
      blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or
      parenteral dose and folic acid in rheumatoid arthritis patients who are not receiving
      adequate response to methotrexate alone up to week 30.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK equivalence to remicade</measure>
    <time_frame>PK sampling at week 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>up to week 54.</time_frame>
    <description>-ACR criteria comparison with Baseline at Weeks 14,30,54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- Time to onset of ACR20 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- Mean decrease in disease activity measured by DAS28 comparison with Baseline at week 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- Proportion of patients with a good response, defined according to the EULAR response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- ACR20 at weeks 14 and 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- ACR50 and ACR70 at weeks 14, 30, and 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- Hybrid ACR response at weeks 14, 30, and 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- SDAI and CDAI at weeks 14, 30, and 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- Joint damage progression at week 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- SF-36 at weeks 14, 30, and 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- Fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy endpoint</measure>
    <time_frame>Up to week 54.</time_frame>
    <description>- Number of patients requiring salvage retreatment at weeks 30 and 54</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">617</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CT-P13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.</description>
    <arm_group_label>CT-P13</arm_group_label>
    <arm_group_label>Remicade</arm_group_label>
    <other_name>remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with active rheumatoid arthritis

          -  at least 3 months of treatment with methotrexate

        Exclusion Criteria:

          -  have allergies to infliximab

          -  serious infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Hyun Yoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

